Sachetta LLC Makes New $518,000 Investment in Danaher Co. (NYSE:DHR)

Sachetta LLC acquired a new stake in shares of Danaher Co. (NYSE:DHR) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 2,239 shares of the conglomerate’s stock, valued at approximately $518,000.

Other hedge funds have also recently modified their holdings of the company. Banco Santander S.A. bought a new stake in shares of Danaher in the 3rd quarter worth about $683,000. Cary Street Partners Investment Advisory LLC grew its holdings in Danaher by 20.2% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after purchasing an additional 1,533 shares during the last quarter. First Citizens Bank & Trust Co. grew its holdings in Danaher by 0.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock valued at $6,156,000 after purchasing an additional 149 shares during the last quarter. Cercano Management LLC grew its holdings in Danaher by 11.4% during the 4th quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock valued at $46,862,000 after purchasing an additional 20,715 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Danaher by 48.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after purchasing an additional 96,395 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of NYSE DHR traded up $1.11 during trading on Monday, hitting $266.91. The company had a trading volume of 1,085,916 shares, compared to its average volume of 2,693,724. The stock has a fifty day simple moving average of $248.74 and a two-hundred day simple moving average of $236.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $267.64. The firm has a market capitalization of $197.70 billion, a price-to-earnings ratio of 45.05, a price-to-earnings-growth ratio of 4.09 and a beta of 0.83. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period last year, the firm posted $2.36 earnings per share. On average, research analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on DHR shares. Royal Bank of Canada upped their target price on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Barclays raised their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. Robert W. Baird increased their price objective on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Finally, KeyCorp increased their price objective on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $267.31.

Insider Buying and Selling at Danaher

In other Danaher news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares in the company, valued at $28,304,483.16. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Danaher news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares in the company, valued at $28,304,483.16. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The disclosure for this sale can be found here. Insiders sold a total of 172,540 shares of company stock worth $43,523,481 over the last three months. Insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.